Diligence memo · auto-generated · as of July 3, 2026

Fresenius Medical Care Locust Grove, LLC

Fresenius Medical Care Locust Grove, LLC looks over-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Fresenius Medical Care Locust Grove, LLC operates in Healthtech, based in WALTHAM.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Fresenius Medical Care Locust Grove, LLC has raised $556K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $556K on 2019-05-02.

Most recent recorded round closed around 2019-05-02.

Valuation (modeled)modeled

Provath models Fresenius Medical Care Locust Grove, LLC at approximately $19M (range $348K–$217M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 1.85× the median modeled value of Pre-Seed Healthtech companies in 2019–2021 (139 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Last raise 7.2 yr ago; this sector typically re-raises about every 14 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 22% of Healthtech peers (2138 compared).

Modeled value ranks above 44% of those peers.

Closest niche peers: Levin Eye Care LLC, Medical Records Now, Inc., Emf Medical Devices Inc., Miracle Leaf Health Centers, Corp., PRINE Health Holdings, LLC.

Peoplefiled

6 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.